摘要
目的 分析荷丹片联合氟伐他汀治疗冠心病患者血清低密度脂蛋白（LDL）与心率变异性的影响。方法 选取2015年3月～2016年6月于嘉兴市中医医院治疗的冠心病患者110例为研究对象,随机分为观察组和对照组,每组各55例。观察组使用荷丹片联合氟伐他汀治疗,对照组使用氟伐他汀治疗,对比2组治疗前后心率变异性、血脂水平、炎性因子水平变化,观察治疗后临床疗效。结果 治疗后,观察组总有效率为96.4%,明显高于对照组85.5%,差异有统计学意义（P〈0.05）;观察组的全部窦性心搏RR间期（SDNN）为（85.42±9.11）ms、RR间期平均值标准差（SDANN）为（49.11±5.13）ms,显著高于对照组的（76.87±8.12）ms、（44.16±4.76）ms,差异有统计学意义（P〈0.05）;观察组总胆固醇（TC）为（4.14±0.45）mmol/L、甘油三酯（TG）为（1.26±0.16）mmol/L、低密度脂蛋白（LDL）为（2.08±0.31）mmol/L,水平显著低于对照组的（4.78±0.51）mmol/L、（1.42±0.18）mmol/L、（2.43±0.27）mmol/L,高密度脂蛋白（HDL）为（1.51±0.18）mmol/L,显著高于对照组（1.35±0.15）mmol/L,差异有统计学意义（P〈0.05）;观察组炎性因子水平均明显的低于对照组,差异有统计学意义（P〈0.05）。结论 荷丹片联合氟伐他汀治疗冠心病,可有效降低血清LDL水平,改善心率变异性,显著提高治疗效果。
Objective To investigate the effect of Hedan tablet combined with fluvastatin on serum LDL and heart rate variability in patients with coronary atherosclerotic heart disease （CHD）.Methods 110 patients with coronary heart disease who were treated from March 2015 to June 2016 in our hospital were selected and randomly divided into observation group and control group, with 55 cases in each group.The patients in the observation group were treated with Hedan tablet combined with fluvastatin, and the control group was treated with fluvastatin.The changes of heart rate variability, blood lipids and inflammatory factors were compared before and after treatment, and the clinical curative effect was observed.Results After treatment, the total effective rate of the observation group was 96.4%, significantly higher than the control group 85.5%, the difference was statistically significant （P〈0.05）.The SDNN of the observation group was （85.42 ±9.11） ms and the SDANN was （49.11 ±5.13） ms, was significantly higher than those in the control group （76.87 ±8.12） ms, （44.16 ±4.76） ms.In the observation group, TC was （4.14 ±0.45） mmol/L, TG was （1.26 ±0.16） mmol/L, LDL was （2.08 ±0.31） mmol/L, significantly lower than the control group （4.78 ±0.51） mmol/L, （1.42 ±0.18） mmol/L, （2.43 ± 0.27） mmol/L, and HDL levels was （1.51 ±0.18） mmol/L, significantly higher than those in the control group （1.35 ±0.15） mmol/L, the difference was statistically significant （P〈0.05）, and the levels of inflammatory factors in the observation group were significantly lower than those in the control group, the difference was statistically significant （P〈0.05）.Conclusion Hedan tablets combined with fluvastatin in treating coronary atherosclerotic heart disease can effectively reduce serum LDL levels, improve heart rate variability, significantly improve the treatment effect.
出处
《中国生化药物杂志》
CAS
2017年第3期116-118,共3页
Chinese Journal of Biochemical Pharmaceutics
关键词
荷丹片
联合
氟伐他汀
冠心病
血清LDL
心率变异性
Hedan tablet
combine
fluvastatin
coronary atherosclerotic heart disease
serum LDL
heart rate variability
